Tags : Commercialization

Roche Signs a Development and Commercialization Agreement with Dicerna for

Shots: Dicerna to receive $200M up front and up to $1.47B development, regulatory and commercial milestones and royalties based on the sales of DCR-HBVS. Roche to get WW license to develop & commercialize DCR-HBVS utilizing Dicerna’s GalXC RNAi platform technology Dicerna holds an option to co-fund global development of DCR-HBVS, which if exercised, Dicerna will […]Read More

GE Healthcare Signs a Worldwide Development and Commercialization Agreement with

Shots: The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer, GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer   The companies […]Read More

Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for

Shots: Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development, manufacturing and supply of proposed biosimilar natalizumab The focus of the agreement is to expand Novartis/Sandoz’s portfolio across small molecules, complex generics, biosimilars, and innovator therapies with the addition […]Read More

Pharming Signs an Exclusive Development and Commercialization Agreement with Novartis

Shots: Novartis to receive $20M (€17.9M) up front, regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally, Pharming will work with Novartis for enrolling patients in ongoing trials   Novartis has accomplished all the preclinical and clinical activities regarding product and will continue […]Read More

Regenxbio Signs an Exclusive Development and Commercialization Agreement with Neurimmune

Shots: Regenxbio and Neurimmune enter into a collaboration to develop vectorized Ab by combining antibodies identified using Neurimmune’s reverse translational medicine platform with Regenxbio’s NAV technology platform for chronic neuro-degenerative diseases including tauopathies The companies will jointly develop & commercialize AVV gene therapies with equal development cost-sharing with an initial focus on tauopathies. Following initial […]Read More

Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for

Shots: Alvotech will take care of development and supply of the product while Cipla Gulf, subsidiary of Cipla will be responsible for Alvotech’s AVT02 registration and commercialization The agreement will allow Alvotech to have access for Cipla’s strong commercial network in selected emerging markets enabling patients with high-quality biosimilars Alvotech’s AVT02 is a mAb and […]Read More

Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for

Shots: Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque, Omniscan, including Visipaque, Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020 GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the […]Read More